Answers are grounded in this paper and cite their sources.
Immunomodulatory agents with the potential to reverse critical COVID-19, targeting host-virus immune response are needed. In this exploratory sub study of a randomised controlled clinical trial, critical COVID-19 patients with moderate acute respiratory distress syndrome at one Swedish university hospital were randomly assigned (1:1) to hyperbaric oxygen therapy (HBOT) group plus best practice, or best practice (Control). Follow-up was 30 days. HBOT was administered with five treatments at 2.4 atmospheres absolute (ATA), lasting 80 minutes, within the first seven days. Clinical outcome, inflammatory markers, and bulk RNA sequencing (RNAseq) on peripheral blood mononuclear cells were analysed. Between December 3 rd , 2020, and May 17 th , 2021, 23 patients were randomised, and 17 were analysed. RNA-sequencing revealed 791 differentially expressed genes in the HBOT group compared to 46 in the control group at Day 7 vs. baseline. Gene set enrichment analysis revealed a unique transcriptomic signature associated with endoplasmic reticulum stress (ERS) in the HBOT group. Patients in the HBOT group recovered faster and had a shorter mean hospital length of stay (HLoS), 16 vs. 26 days (95.99% CI -16-0), p=0.045. National early warning score (NEWS) was lower in the HBOT group (ANOVA, F [8, 120] = 3.817, p < 0.001) and PaO 2 /FiO 2 was higher in the HBOT group (Mixed effects model, F [8, 94] = 2.900, p < 0.01). We showed a unique transcriptomic signature related to viral-induced ERS in critically ill COVID-19 patients treated with HBOT. The finding was associated with a positive clinical outcome; the HBOT patients recovered faster and had a reduced HLoS compared with controls. NCT04327505 (31/03/2020) and EudraCT 2020-001349-37 (24/04/2020) • Transcriptomic changes associated with HBOT in severe and critical COVID-19 patients are investigated in a randomised controlled trial . • Critically ill COVID-19 patients treated with HBOT recovered faster and had a reduced HLoS compared to controls. The clinical outcome was associated with a unique transcriptomic signature related to viral-induced endoplasmic reticulum stress. • The association between the clinical course of disease and transcriptomic signature is hypothesis-generating for future pharmacological interventions and understanding of the virus-host interactions and immune response.
No takes yet. Share an insight, caveat, or question.
Kjellberg et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: